Teleflex (TFX) has drawn fresh attention after releasing new clinical results for its Interventional Urology products, the UroLift System and Barrigel rectal spacer, at the AUA and ESTRO 2026 congresses, highlighting patient-centered outcomes.

Teleflex’s recent Interventional Urology data and dividend affirmation come as the stock trades at US$131.89, with the share price up 17.87% over 90 days but long term total shareholder returns still well below five year levels. This suggests recent momentum is rebuilding from a weaker multi year base.

If this kind of clinical and dividend story has your attention, it can be a good moment to broaden your research and uncover 34 healthcare AI stocks

With Teleflex trading at US$131.89, sitting on an 8.9% gap to analyst targets and an indicated 41.1% intrinsic discount, investors now face a key question: is this genuine undervaluation, or is the market already pricing in future growth?

Most Popular Narrative: 2% Overvalued

Teleflex’s most followed narrative pegs fair value at $129.25 using an 8.9% discount rate, slightly below the last close at $131.89. This sets up a tight valuation debate.

The company's focus on portfolio optimization and potential separation or sale of business segments (e.g., NewCo), with anticipated proceeds deployed for debt paydown and shareholder returns, could unlock value and increase net margins and EPS through a more focused, streamlined operating model.

Want to see the full playbook behind that fair value line? The narrative leans on faster earnings expansion, richer margins, and a future earnings multiple that tells a very different story from today.

Result: Fair Value of $129.25 (OVERVALUED)

However, this hinges on UroLift weakness and ongoing margin pressures not deepening, and on the BIOTRONIK integration avoiding cost overruns or disruption to earnings.

Another Angle on Teleflex’s Valuation

The narrative model has Teleflex 2% overvalued around a fair value of $129.25, yet Simply Wall St’s DCF model points to a future cash flow value of $223.78, or a 41.1% gap to the current $131.89 price. Two frameworks, one stock: which one feels closer to how you think about risk?

Next Steps

Curious whether the balance of risks and rewards here matches your own read of Teleflex? Take a close look at the underlying data, weigh both angles carefully, and then pressure test your view against our breakdown of 2 key rewards and 3 important warning signs

Looking for more investment ideas?

Before you move on, give yourself a chance to spot opportunities you might otherwise miss by running a few focused screens tailored to different goals.

• Zero in on financially robust businesses by scanning the solid balance sheet and fundamentals stocks screener (46 results), which may better handle bumps in the road.
• Hunt for potential value by reviewing the 46 high quality undervalued stocks, which pair quality fundamentals with pricing that may not fully reflect them.
• Broaden your opportunity set by checking the screener containing 22 high quality undiscovered gems, which sit off the usual radars yet still show solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.